The main risk is sequencing. Stem appears to own a real control-software wedge, but liquidity binds before most other advantages matter and can force
dilution or creditor-favorable outcomes. The next layer of risk is competitive and structural: if buyers accept
OEM-native or cheaper orchestration layers, Stem may grow with the market yet still fail to capture enough of the value to produce a major shareholder win.